Eupraxia Pharmaceuticals (EPRX) Restructuring Costs (2024 - 2026)
Eupraxia Pharmaceuticals' (EPRX) quarterly Restructuring Costs came in at $1.9 million in Q1 2026, up 34.94% year-on-year from $1.4 million in Q1 2025, and up 30.54% on a QoQ basis from $1.5 million in Q3 2025.
Eupraxia Pharmaceuticals (EPRX) Restructuring Costs (2024 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 3 years of Restructuring Costs data on file, last reported at $1.9 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.94 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | 1.59 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.84 Mn |